Striatal dopamine receptor plasticity in neurotensin deficient mice.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Behavioural Brain Research

• Publication date

  2015-03-01

• Fields of study

  Biology, Medicine, Chemistry, Psychology

• Identifiers
  DOI 10.1016/j.bbr.2014.11.014PMID 25449842PMCID PMC4496790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diverse Roles of Neurotensin Agonists in the Central Nervous System

  2013cited by this paper
• Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice.

  2013cited by this paper
• A systematic review of psychostimulant treatment of negative symptoms of schizophrenia: challenges and therapeutic opportunities.

  2013cited by this paper
• The role of endogenous neurotensin in psychostimulant-induced disruption of prepulse inhibition and locomotion.

  2012cited by this paper
• All Roads to Schizophrenia Lead to Dopamine Supersensitivity and Elevated Dopamine D2High Receptors

  2011cited by this paper
• Neurotensin Triggers Dopamine D2 Receptor Desensitization through a Protein Kinase C and β-Arrestin1-dependent Mechanism*

  2011cited by this paper
• The canary in the coalmine: the sensitivity of mesolimbic dopamine to environmental adversity during development.

  2011cited by this paper
• Hyperactivity of the dopaminergic system in NTS1 and NTS2 null mice.

  2010cited by this paper
• Negative symptoms in schizophrenia: avolition and Occam's razor.

  2010cited by this paper
• Assessment of Pharmacotherapy for Negative Symptoms of Schizophrenia

  2010cited by this paper
• Cocaine-induced sensitization is associated with altered dynamics of transcriptional responses of the dopamine transporter, tyrosine hydroxylase, and dopamine D2 receptors in C57Bl/6J mice

  2007cited by this paper
• Psychosis pathways converge via D2High dopamine receptors

  2006cited by this paper
• Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons

  2006cited by this paper
• Amphetamine-elicited striatal Fos expression is attenuated in neurotensin null mutant mice.

  2006cited by this paper
• Neurotensin-Deficient Mice Have Deficits in Prepulse Inhibition: Restoration by Clozapine but Not Haloperidol, Olanzapine, or Quetiapine

  2005cited by this paper
• Amphetamine and negative symptoms of schizophrenia

  2005cited by this paper
• Increased caudate dopamine D2 receptor availability as a genetic marker for schizophrenia.

  2005cited by this paper
• Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease

  2005cited by this paper
• Provocative tests with psychostimulant drugs in schizophrenia

  2004cited by this paper
• Neurotensin Receptor Antagonist SR 142948A Alters Fos Expression and Extrapyramidal Side Effect Profile of Typical and Atypical Antipsychotic Drugs

  2004cited by this paper
• Dopamine D1 Rather than D2 Receptor Agonists Disrupt Prepulse Inhibition of Startle in Mice

  2003cited by this paper
• The Mouse Brain in Stereotaxic Coordinates

  2001cited by this paper
• The neurotensin antagonist SR 48692 attenuates haloperidol-induced striatal Fos expression in the rat.

  2001cited by this paper
• The neurotensin receptor antagonist, SR48692, attenuates the expression of amphetamine-induced behavioural sensitisation in mice.

  2001cited by this paper
• Neurotensin-deficient mice show altered responses to antipsychotic drugs

  2001cited by this paper
• Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

  2001cited by this paper
• Neurotensin and dopamine interactions.

  2001cited by this paper
• Schizophrenia: more dopamine, more D2 receptors.

  2000cited by this paper
• Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors.

  2000cited by this paper
• Dopamine control of striatal gene expression during development: relevance to knockout mice for the dopamine transporter

  2000cited by this paper
• Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol.

  2000cited by this paper
• Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter

  2000cited by this paper
• Profound neuronal plasticity in response to inactivation of the dopamine transporter.

  1998cited by this paper
• Mode matches in hydrophobic free energy eigenfunctions predict peptide-protein interactions.

  1998cited by this paper
• Quantification of Neuroreceptors in the Living Human Brain: IV. Effect of Aging and Elevations of D2-Like Receptors in Schizophrenia and Bipolar Illness

  1997cited by this paper
• CSF neurotensin concentrations and antipsychotic treatment in schizophrenia and schizoaffective disorder.

  1997cited by this paper
• Dopamine transporter mRNA is up-regulated in the substantia nigra and the ventral tegmental area of amphetamine-sensitized rats.

  1997cited by this paper
• Mitochondrial toxins in models of neurodegenerative diseases. II: Elevated zif268 transcription and independent temporal regulation of striatal D1 and D2 receptor mRNAs and D1 and D2 receptor-binding sites in C57BL/6 mice during MPTP treatment.

  1997cited by this paper
• DAD1‐ and DAD2‐like agonist effects on motor activity of C57 mice: Differences compared to rats

  1997cited by this paper
• Dopamine-cell depolarization block as a model for the therapeutic actions of antipsychotic drugs.

  1997cited by this paper
• No elevated D2 dopamine receptors in neuroleptic-naive schizophrenic patients revealed by positron emission tomography and [11C]N-methylspiperone.

  1995cited by this paper
• Effects of SR 48692, a selective non-peptide neurotensin receptor antagonist, on two dopamine-dependent behavioural responses in mice and rats

  1994cited by this paper
• CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates.

  1994cited by this paper
• Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.

  1993cited by this paper
• Evidence for a substrate of neuronal plasticity based on pre- and postsynaptic neurotensin-dopamine receptor interactions in the neostriatum.

  1992cited by this paper
• Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients.

  1991cited by this paper
• The Mouse Dopamine D2A Receptor Gene: Sequence Homology with the Rat and Human Genes and Expression of Alternative Transcripts

  1991cited by this paper
• Neurotensin modulates autoreceptor mediated dopamine effects on midbrain dopamine cell activity.

  1991cited by this paper
• Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

  1991cited by this paper
• D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

  1990cited by this paper
• Neurotensin attenuates dopamine D2 agonist quinpirole-induced inhibition of midbrain dopamine neurons.

  1990cited by this paper
• Neurotensin-like immunoreactivity in cerebrospinal fluid of patients with schizophrenia, depression, anorexia nervosa-bulimia, and premenstrual syndrome.

  1989cited by this paper
• Reduced CSF neurotensin concentration in drug-free schizophrenic patients.

  1988cited by this paper
• Dopamine receptors and the dopamine hypothesis of schizophrenia

  1987cited by this paper
• Parallel organization of functionally segregated circuits linking basal ganglia and cortex.

  1986cited by this paper
• SUBNORMAL CSF LEVELS OF NEUROTENSIN IN A SUBGROUP OF SCHIZOPHRENICS AND NORMALIZATION AFTER NEUROLEPTIC TREATMENT

  1982cited by this paper
• Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: normalization after neuroleptic treatment.

  1982cited by this paper
• Neurotensin: perchance an endogenous neuroleptic?

  1980cited by this paper
• Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain.

  1977cited by this paper
• The dopamine hypothesis of schizophrenia: a review.

  1976cited by this paper
• The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.

  1966cited by this paper
• The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.

  1966cited by this paper
• Protein measurement with the Folin phenol reagent.

  1951cited by this paper

• Angiotensin‐converting enzymes as druggable features of psychiatric and neurodegenerative disorders

  2023cites this paper
• Opioid Analgesia and Opioid-Induced Adverse Effects: A Review

  2021cites this paper
• Dopamine transporter gene expression within the nucleus accumbens plays important role in the acquisition and reinstatement of ethanol-seeking behavior in mice.

  2020cites this paper
• Decreased nuclear distribution nudE-like 1 enzyme activity in an animal model with dysfunctional disrupted-in-schizophrenia 1 signaling featuring aberrant neurodevelopment and amphetamine-supersensitivity

  2020cites this paper
• ACE activity in blood and brain axis in an animal model for schizophrenia: Effects of dopaminergic manipulation with antipsychotics and psychostimulants

  2020cites this paper
• NEUROPEPTIDES AND OLIGOPEPTIDASES IN SCHIZOPHRENIA.

  2019cites this paper
• Impact of nuclear distribution element genes in the typical and atypical antipsychotics effects on nematode Caenorhabditis elegans: Putative animal model for studying the pathways correlated to schizophrenia

  2019influential citation
• Effect on the dopaminergic metabolism induced by oral exposure to simazine during the prepubertal period in rats.

  2017cites this paper
• Le rôle de la neurotensine dans l’expression de la sensibilisation dopaminergique induite par un traitement continu aux antipsychotiques

  2016cites this paper